Clinical Trials Logo

Chronic Myelocytic Leukemia clinical trials

View clinical trials related to Chronic Myelocytic Leukemia.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04256317 Recruiting - Clinical trials for Acute Myeloid Leukemia

A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AML

Start date: May 21, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

Study ASTX030-01 is designed to move efficiently from Phase 1 to Phase 3. Phase 1 consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at escalating dose levels of oral cedazuridine and azacitidine (only one study drug will be escalated at a time) followed by a Dose Expansion Stage (Stage B) of ASTX030. Phase 2 is a randomized open-label crossover study to compare oral ASTX030 to subcutaneous (SC) azacitidine. Phase 3 is a randomized open-label crossover study comparing the final oral ASTX030 dose to SC azacitidine. The duration of the study is expected to be approximately 48 months.

NCT ID: NCT04150471 Recruiting - Clinical trials for Chronic Myelocytic Leukemia

Assess Long-term Feasibility of Reduced Dose Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients

Start date: October 18, 2018
Phase:
Study type: Observational

This study is conducted in patients with newly diagnosed CP CML (Chronic Phase Chronic Myeloid Leukemia) who have achieved EMR (< 10% IS BCR-ABL) at 3 months after first line treatment with dasatinib. Subjects will be allocated to 80mg QD based on EMR (Early Molecular Response) achievement and early safety profile following a standard of care approach.